Dipal Doshi

CIK: 0001613084

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)10 (71.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TRDA

Entrada Therapeutics, Inc.

DirectorOfficer

AZTA

Azenta, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (14 total)

TRDA
Entrada Therapeutics, Inc.
Sep 2, 2026
Tax Payment(F)
Direct
8.7K shares at avg. $7.14$62K
TRDA
Entrada Therapeutics, Inc.
Mar 3, 2026
Tax Payment(F)
Direct
19.2K shares at avg. $11.76$225K
TRDA
Entrada Therapeutics, Inc.
Mar 2, 2026
Tax Payment(F)
Direct
9.9K shares at avg. $11.66$115K
TRDA
Entrada Therapeutics, Inc.
Mar 1, 2026
Award(A)
Direct
139.4K shares-
AZTA
Azenta, Inc.
Feb 5, 2026
Award(A)
Direct
5.7K shares at avg. $27.85$158K
TRDA
Entrada Therapeutics, Inc.
Sep 2, 2025
Tax Payment(F)
Direct
8.7K shares at avg. $5.43$47K
TRDA
Entrada Therapeutics, Inc.
Mar 3, 2025
Tax Payment(F)
Direct
17.6K shares at avg. $11.68$205K
TRDA
Entrada Therapeutics, Inc.
Mar 1, 2025
Award(A)
Direct
116.2K shares-
AZTA
Azenta, Inc.
Feb 7, 2025
Award(A)
Direct
4K shares at avg. $52.32$211K
TRDA
Entrada Therapeutics, Inc.
Sep 5, 2024
Tax Payment(F)
Direct
826 shares at avg. $15.13$12K
TRDA
Entrada Therapeutics, Inc.
Sep 4, 2024
Tax Payment(F)
Direct
4.7K shares at avg. $15.42$73K
TRDA
Entrada Therapeutics, Inc.
Sep 3, 2024
Tax Payment(F)
Direct
752 shares at avg. $16.93$13K
TRDA
Entrada Therapeutics, Inc.
Sep 3, 2024
Tax Payment(F)
Direct
2.3K shares at avg. $15.76$37K
TRDA
Entrada Therapeutics, Inc.
Sep 3, 2024
Tax Payment(F)
Direct
72 shares at avg. $17.70$1K

		Type	Shares	Price		Ownership
Sep 2, 2026	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	8,724	$7.14	$62,323	Direct
Mar 3, 2026	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	19,181	$11.76	$225,500	Direct
Mar 2, 2026	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	9,869	$11.66	$115,052	Direct
Mar 1, 2026	TRDA Entrada Therapeutics, Inc.	Award(A)	139,400	-	$0	Direct
Feb 5, 2026	AZTA Azenta, Inc.	Award(A)	5,663	$27.85	$157,715	Direct
Sep 2, 2025	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	8,723	$5.43	$47,368	Direct
Mar 3, 2025	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	17,566	$11.68	$205,146	Direct
Mar 1, 2025	TRDA Entrada Therapeutics, Inc.	Award(A)	116,200	-	-	Direct
Feb 7, 2025	AZTA Azenta, Inc.	Award(A)	4,040	$52.32	$211,373	Direct
Sep 5, 2024	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	826	$15.13	$12,494	Direct
Sep 4, 2024	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	4,744	$15.42	$73,169	Direct
Sep 3, 2024	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	752	$16.93	$12,728	Direct
Sep 3, 2024	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	2,328	$15.76	$36,692	Direct
Sep 3, 2024	TRDA Entrada Therapeutics, Inc.	Tax Payment(F)	72	$17.70	$1,275	Direct

1-14 of 14 transactions

About Doshi Dipal

Doshi Dipal (SEC CIK 0001613084) files insider reports with the SEC as CEO of Entrada Therapeutics, Inc. (TRDA) and Director of Azenta, Inc. (AZTA).

Signal8 holds 8 ownership filings by Doshi Dipal (1 Form 3, 7 Form 4), filed between Sep 5, 2024 and Sep 3, 2026. Those filings report 14 transactions, from Sep 3, 2024 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Doshi Dipal's filings is in BOSTON, MA.

Recent filings by Doshi Dipal

Sep 2, 2026: Tax withholding of TRDA shares (Form 4, code F).
Mar 3, 2026: Tax withholding of TRDA shares (Form 4, code F).
Mar 2, 2026: Tax withholding of TRDA shares (Form 4, code F).
Mar 1, 2026: Grant or award of TRDA shares (Form 4, code A).
Feb 5, 2026: Grant or award of AZTA shares (Form 4, code A).

Other insiders filing for Entrada Therapeutics, Inc. (TRDA)

MPM BIOVENTURES 2018, L.P., 10% Owner
MPM BioVentures 2014, L.P., 10% Owner
Dowden Nathan J, President & COO
Sethuraman Natarajan, President, Research & Develop.
WENTWORTH KORY JAMES, Chief Financial Officer
PARMAR KUSH, Director

How to read Form 4 transaction codes